Iridoid and Acyclic Monoterpene Glycosides, Kankanosides L, M, N, O, and P from *Cistanche tubulosa*

Toshio MORIKAWA,^a Yingni PAN,^{a,b} Kiyofumi NINOMIYA,^a Katsuya IMURA,^a Dan YUAN,^b Masayuki YOSHIKAWA,^{a,c} Takao HAYAKAWA,^a and Osamu MURAOKA^{*,a}

^a Pharmaceutical Research and Technology Institute, Kinki University; 3–4–1 Kowakae, Higashi-osaka, Osaka 577–8502, Japan; ^b School of Traditional Chinese Medicine, Shenyang Pharmaceutical University; 103 Wenhua Rd., Shenyang 110016, People's Republic of China; and ^c Kyoto Pharmaceutical University; Misasagi, Yamashina-ku, Kyoto 607–8412, Japan. Received June 12, 2010; accepted July 14, 2010; published online July 15, 2010

Three iridoid glycosides, kankanosides L, M, and N, and two acyclic monoterpene glycosides, kankanosides O and P, were isolated from fresh stems of *Cistanche tubulosa* (Orobanchaceae) together with eight iridoid glycosides, five acyclic monoterpene glycosides, three phenylpropanoid glycosides, and four lignan glycosides. Their structures were elucidated on the basis of chemical and physicochemical evidence.

Key words *Cistanche tubulosa*; kankanoside; iridoid; acyclic monoterpene; Orobanchaceae

Cistanche tubulosa (SCHRENK) R. WIGHT (Orobanchaceae) is a perennial parasitic plant growing on roots of *Salvadora* or *Calotropis* species, distributed in North Africa, Arabia, and Asian countries.¹⁾ Stems of this plant (Kanka-nikujuyou in Japanese) have traditionally been used for treatment of impotence, sterility, lumbago, and body weakness as well as a promoting agent of blood circulation.^{1,2)} During the course of our studies on bioactive constituents from stems of *C. tubulosa*,^{3–6)} we previously reported twenty four phenylethanoid oligoglycosides including kankanosides H₁, H₂, I, J₁, J₂, K₁, and K₂, and two acylated oligosugars from fresh stems of *C. tubulosa*.^{5,6)} Furthermore, principal phenylethanoid glycosides, echinacoside, acteoside, and isoacteoside, were found to inhibit increase in serum aspartate aminotransferase (sAST) and alanine aminotransferase (sALT) levels in the mice's injured liver induced by D-galactosamine (D-GalN)/lipopolysaccharide at doses of 25–100 mg/kg *per os* (*p.o.*). Structural requirements of the phenylethanoid glycosides for the hepatoprotective activity were also elucidated.⁵⁾ In this continuing study on constituents in the fresh stems of *C. tubulosa*, we further isolated eleven iridoid glycosides including kankanosides L (1), M (2), and N (3), seven acyclic monoterpene glycosides including kankanosides O (4) and P (5), three phenylpropanoids, and four lignans. This paper deals with isolation and structure elucidation of five new compounds (1–5).

Fresh stems of *C. tubulosa* (cultivated in Urumuqi, Xinjiang Province, China) were extracted with methanol under

reflux to yield a methanolic extract (8.36% from the fresh stems). From the methanolic extract, H₂O- and MeOH-eluted fractions (5.63% and 2.73%, respectively) were obtained by Diaion HP-20 column chromatography (H₂O→MeOH) as described previously.⁵⁾ The MeOH-eluted fraction was subjected to SiO₂ and ODS column chromatographies and finally HPLC to furnish kankanosides L (1, 0.0026%), M (2, 0.0001%), N (3, 0.0007%), O (4, 0.0020%), and P (5, 0.0002%), 6-deoxycatalpol^{3,7)} (6, 0.197%), bartsioside^{3,7)} (7, 0.0583%), glucoside^{3,7)} (8, 0.0443%), kankanoside A³⁾ (9, 22.3 mg, 0.0010%), mussaenosidic acid^{3,7)} (10, 0.0056%), 8-epiloganic acid^{3,8)} (11, 0.0023%), 8-epideoxyloganic acid^{3,7)} (12, 0.0004%), geniposidic acid^{3,7)} (13, 0.0040%), kankanoside E³⁾ (14, 0.0026%), (2*E*,6*Z*)-8-β-D-glucopyranosyloxy-2,6-dimethyl-2,6-octadienoic acid^{3,9)} (15, 31.0 mg, 0.0014%), (2*E*,6*E*)-3,7-dimethyl-8-hydroxyoctadien-1-yl-*O*-β-D-glucopyranoside¹⁰⁾ (16, 0.0082%), 8-hydroxygeraniol 8-*O*-β-D-glucopyranoside¹¹⁾ (17, 0.0044%), betulalbuside A¹²⁾ (18, 0.0004%), coniferin¹³⁾ (19, 0.0002%), syringin¹³⁾ (20, 0.0015%), sinapic aldehyde 4-*O*-β-D-glucopyranoside¹⁴⁾ (21, 0.0001%), (+)-pinosresinol *O*-β-D-glucopyranoside^{4,8,15)} (22, 0.0010%), eucommin A¹⁶⁾ (23, 0.0002%), isoeucommin A¹⁷⁾ (24, 0.0010%), and (+)-syringaresinol *O*-β-D-glucopyranoside^{4,8,18)} (25, 0.0044%).

Structures of Kankanosides L (1), M (2), and N (3) Kankanoside L (1) was obtained as a white powder with negative optical rotation ($[\alpha]_D^{26} -45.7$ in MeOH). Its IR spectrum showed strong absorption band at 3433 and 1080 cm⁻¹ suggestive of a glycoside moiety. The fast atom bombardment (FAB)-MS of 1 run in the positive- and negative-ion modes showed quasimolecular ion peaks at *m/z* 371 [M+Na]⁺ and 347 [M-H]⁻, respectively, and the molecular formula was determined as C₁₅H₂₄O₉ by high-resolution FAB-MS measurement. Acid hydrolysis of 1 with 1.0 M hydrochloric acid (HCl) liberated D-glucose, which was identified by HPLC analysis using an optical rotation detector.^{3–6)} The ¹H- and ¹³C-NMR spectra of 1 (CD₃OD, Tables 1, 2), which were assigned by various NMR experiments,¹⁹⁾ showed signals assignable to four methylenes [δ 1.43 (1H, br dd, *J*=ca. 5, 13 Hz, 4α-H), 1.73 (1H, br dd, *J*=ca. 12, 14 Hz, 6α-H), 1.85 (1H, m, 4β-H), 1.93 (1H, br dd, *J*=ca. 8, 14 Hz, 6β-H), 3.50 (1H, ddd, *J*=2.4, 12.5, 13.0 Hz, 3α-H), 3.83 (1H, br dd, *J*=

Chart 1

* To whom correspondence should be addressed. e-mail: muraoka@phar.kindai.ac.jp

Chart 2

Table 1. ¹H-NMR Data (600 MHz, CD₃OD) for Kankanosides L (1), M (2), and N (3)

Position	1	2	3
	δ (J Hz)	δ (J Hz)	δ (J Hz)
1	4.81 (d, 8.9)		4.67 (d, 7.4)
3α	3.50 (ddd, 2.4, 12.5, 13.0)	4.35 (ddd, 3.1, 6.7, 14.3)	3.70 (dd, 3.3, 12.0)
3β	3.83 (br dd, ca. 5, 13)	4.29 (ddd, 2.8, 8.4, 14.3)	3.88 (m)
4α	1.43 (br dd, ca. 5, 13)	1.66 (m)	1.69 (m)
4β	1.85 (m)	2.11 (m)	
5	2.23 (m)	2.97 (m)	2.16 (m)
6α	1.73 (br dd, ca. 12, 14)	2.15 (m)	1.65 (m)
6β	1.93 (br dd, ca. 8, 14)	2.75 (m)	1.81 (m)
7(α)	3.46 (br s)	5.94 (m)	1.37 (m)
7β			1.87 (m)
8			2.06 (m)
9	2.15 (dd, 7.2, 8.9)	3.82 (br s)	1.75 (m)
10	3.78, 4.12 (both d, 13.1)	4.32, 4.51 (both d, 13.1)	1.07 (3H, d, 7.2)
11			3.65 (dd, 9.1, 9.8) 3.90 (dd, 5.9, 9.8)
Glc-1'	4.70 (d, 7.9)	4.32 (d, 7.9)	4.26 (d, 7.9)
2'	3.23 (dd, 7.9, 8.9)	3.19 (dd, 7.9, 9.1)	3.17 (dd, 7.9, 9.2)
3'	3.37 (dd, 8.8, 8.9)	3.34 (dd, 9.1, 9.1)	3.35 (dd, 8.6, 9.2)
4'	3.27 (m)	3.28 (dd, 9.1, 9.7)	3.28 (m)
5'	3.27 (m)	3.24 (ddd, 2.2, 5.5, 9.7)	3.25 (m)
6'	3.64 (dd, 5.9, 12.0) 3.89 (dd, 1.9, 12.0)	3.66 (dd, 5.5, 11.8) 3.84 (dd, 2.2, 11.8)	3.67 (dd, 5.5, 11.8) 3.86 (dd, 1.9, 11.8)

ca. 5, 13 Hz, 3β-H), 3.78, 4.12 (1H each, both d, *J*=13.1 Hz, 10-H₂), two methines [*δ* 2.15 (1H, dd, *J*=7.2, 8.9 Hz, 9-H) and 2.23 (1H, m, 5-H)], and an acetal group [*δ* 4.81 (1H, d, *J*=8.9 Hz, 1-H)] together with a β-glucopyranosyl moiety [*δ* 4.70 (d, *J*=7.9 Hz, 1'-H)]. As shown in Fig. 1, the ¹H-¹H correlation spectroscopy (¹H-¹H COSY) experiment on **1** indicated the presence of partial structures written in bold lines. In the heteronuclear multiple-bond correlation (HMBC) experiment on **1**, long-range correlations were

Table 2. ¹³C-NMR Data (150 MHz, CD₃OD) for Kankanosides L (1), M (2), N (3), O (4), and P (5), 4a, and 5a

Position	1	2	3	Position	4	4a	5	5a
1	97.5	174.9	95.2	1	170.1	172.0	171.0	171.7
3	62.6	68.5	62.1	2	128.7	129.5	117.4	118.0
4	26.0	30.7	38.5	3	142.3	142.8	160.5	159.4
5	31.7	36.0	40.0	4	27.2	28.0	41.4	41.5
6	30.7	39.9	28.8	5	38.5	39.2	26.7	26.7
7	60.6	131.9	32.3	6	139.9	138.5	128.5	125.2
8	69.1	138.8	38.0	7	122.0	125.7	134.0	137.0
9	43.9	51.0	46.9	8	65.5	59.4	75.6	68.8
10	61.7	68.4	17.9	9	12.4	12.5	18.8	18.8
11			72.1	10	16.2	16.2	14.1	13.7
Glc-1'	99.4	104.3	104.8	Glc-1'	102.1		102.5	
2'	74.9	75.3	75.2	2'	74.4		75.1	
3'	77.9	78.1	78.1	3'	77.4		78.1	
4'	71.8	71.6	71.6	4'	71.0		71.7	
5'	78.5	78.0	77.9	5'	77.1		77.9	
6'	63.0	62.8	62.7	6'	62.3		62.8

Fig. 1. ¹H-¹H COSY, HMBC, and NOE Correlations for 1–3

observed between the following protons and carbons (1-H and 3-C, 8-C; 3-H and 1-C; 7-H and 8-C, 10-C; 9-H and 8-C; 10-H₂ and 7-C, 8-C; 1'-H and 1-C) as shown in Fig. 1. Next, the relative stereostructure of **1** was characterized by phase-sensitive nuclear Overhauser enhancement spectroscopy (phase-sensitive NOESY) experiment, which showed NOE correlations between the following proton pairs (1-H and 3α-H; 3α-H and 4α-H; 3β-H and 4β-H; 4β-H and 5-H, 9-H; 5-H and 6β-H, 9-H; 6α-H and 7-H; 7-H and 10-H₂), as shown in Fig. 1. The ¹H- and ¹³C-NMR spectra of **1** were superimposable on those of principal iridoid constituent 6-deoxycatalpol (**6**), except for the signals due to the saturated δ-lactone moiety. Finally, hydrogenation of **6** gave **1**, so that the stereostructure of kankanoside L was elucidated to be 3,4-dihydro-6-deoxycatalpol (**1**).

Kankanoside M (**2**) was obtained as a white powder with negative optical rotation ([α]_D²⁶ −18.7 in MeOH). The IR spectrum of **2** showed absorption bands at 3433, 1736, 1655, and 1076 cm^{−1} ascribable to hydroxyl, δ-lactone, olefin, and ether moieties. The positive-ion FAB-MS spectrum of **2** showed a quasimolecular ion peak at *m/z* 353 [M+Na]⁺, and the molecular formula was determined as C₁₅H₂₂O₈ by high-resolution positive-ion FAB-MS measurement. Acid hydrolysis of **2** with 1.0 M HCl liberated D-glucose. The ¹H- and ¹³C-NMR spectra of **2** (CD₃OD, Tables 1, 2) showed signals assignable to four methylenes [*δ* 1.66, 2.11 (1H each, both

m, 4-H₂), 2.15, 2.75 (1H each, both m, 6-H₂), 4.29 (1H, ddd, $J=2.8, 8.4, 14.3$ Hz, 3 β -H), 4.32, 4.51 (1H each, both d, $J=13.1$ Hz, 10-H₂), 4.35 (1H, ddd, $J=3.1, 6.7, 14.3$ Hz, 3 α -H)], two methines [δ 2.97 (1H, m, 5-H), 3.82 (1H, br s, 9-H)], an olefin [δ 5.94 (1H, m, 7-H)], and a saturated lactone group (δ_C 174.9) together with a β -D-glucopyranosyl moiety [δ 4.32 (1H, d, $J=7.9$ Hz, 1'-H)]. As shown in Fig. 1, the ¹H-¹H COSY experiment on **2** indicated the presence of partial structures written in bold lines and, in the HMBC experiment, long-range correlations were observed between the following proton and carbon pairs (3-H and 1-C; 7-H and 9-C; 9-H and 1-C, 8-C; 10-H₂ and 7-C, 8-C, 9-C; 1'-H and 10-C). The relative stereostructure of **2** was characterized by phase-sensitive NOESY experiment, which showed NOE correlations between the following proton pairs (3 α -H and 4 α -H; 3 β -H and 4 β -H; 4 β -H and 5-H; 5-H and 6 β -H, 9-H) as shown in Fig. 1. Thus, the stereostructure of **2** was elucidated as shown.

Kankanoside N (**3**) was isolated as a white powder with negative optical rotation ($[\alpha]_D^{25} -24.6$ in MeOH). In the positive-ion FAB-MS of **3**, a quasimolecular ion peak was observed at m/z 371 $[M+Na]^+$. The molecular formula C₁₆H₂₈O₈ was determined by high-resolution FAB-MS measurement. Acid hydrolysis of **3** with 1.0 M HCl liberated D-glucose. The ¹H- and ¹³C-NMR data (CD₃OD, Tables 1, 2) showed signals assignable to a methyl [δ 1.07 (3H, d, $J=7.2$ Hz, 10-H₃)], four methylenes [δ 1.37, 1.87 (1H each, both m, 7-H₂), 1.65, 1.81 (1H each, both m, 6-H₂), 3.65 (1H, dd, $J=9.1, 9.8$ Hz), 3.90 (1H, dd, $J=5.9, 9.8$ Hz), 11-H₂], and [3.70 (1H, dd, $J=3.3, 12.0$ Hz), 3.88 (1H, m), 3-H₂], four methines [δ 1.69 (1H, m, 4-H), 1.75 (1H, m, 9-H), 2.06 (1H, m, 8-H), 2.16 (1H, m, 5-H)], and a hemiacetal group [δ 4.67 (1H, d, $J=7.4$ Hz, 1-H)] together with a β -D-glucopyranosyl moiety [δ 4.26 (1H, d, $J=7.9$ Hz, 1'-H)]. The iridoid structure of **3** was clarified by ¹H-¹H COSY and HMBC experiments and the relative stereostructure was characterized by phase-sensitive NOESY experiment as shown in Fig. 1. Consequently, the stereostructure of **3** was elucidated as shown.

Structures of Kankanosides O (4) and P (5) Kankanosides O (**4**) and P (**5**), C₁₆H₂₆O₈, were also obtained as white powders with negative optical rotations (**4**: $[\alpha]_D^{23} -26.1$; **5**: $[\alpha]_D^{21} -32.7$ both in MeOH). The IR spectra of **4** and **5** showed absorption bands at 3433, 1696, 1647, and 1076 cm⁻¹ for **4**, and at 3434, 1701, 1647, and 1076 cm⁻¹ for **5**, ascribable to glycosidic, carboxyl, and olefin functions. Their UV spectra showed common absorption maximum at 217 nm indicating the presence of an α,β -unsaturated carboxylic acid moiety in both of them. Acid hydrolysis of **4** and **5** liberated D-glucose, whereas by the enzymatic hydrolysis with β -glucosidase, **4** and **5** gave (2*E*,6*E*)-8-hydroxy-2,6-dimethyl-2,6-octadienoic acid²⁰ (**4a**) and (2*E*,6*E*)-8-hydroxy-3,7-dimethyl-2,6-octadienoic acid²¹ (**5a**), respectively. ¹H- and ¹³C-NMR data of **4** (CD₃OD, Tables 2, 3) showed signals assignable to two methyls [δ 1.71 (3H, br s, 10-H₃), 1.81 (3H, d, $J=1.0$ Hz, 9-H₃)], three methylenes [δ 2.19 (2H, br t, $J=ca. 7$ Hz, 5-H₂), 2.36 (2H, m, 4-H₂), 4.24 (1H, dd, $J=7.6, 12.0$ Hz), 4.33 (1H, dd, $J=6.2, 12.0$ Hz), 8-H₂], and two trisubstituted olefins [δ 5.41 (1H, ddd, $J=1.2, 6.2, 7.6$ Hz, 7-H), 6.75 (1H, tq, $J=7.2, 1.0$ Hz, 3-H)] together with a β -D-glucopyranosyl part [δ 4.34 (d, $J=7.8$ Hz, 1'-H)]. By the comparison of carbon signals in the ¹³C-NMR spectrum of **4**

Table 3. ¹H-NMR Data (600 MHz, CD₃OD) for Kankanosides O (**4**) and P (**5**)

Position	4	5
	δ (J Hz)	δ (J Hz)
2		5.67 (br s)
3	6.75 (tq, 7.2, 1.0)	
4	2.36 (2H, m)	2.24 (2H, m)
5	2.19 (2H, br t, <i>ca.</i> 7)	2.27 (2H, m)
6		5.47 (tq, 7.1, 0.9)
7	5.41 (ddd, 1.2, 6.2, 7.6)	
8	4.24 (dd, 7.6, 12.0)	4.05 (br d, <i>ca.</i> 12)
	4.33 (dd, 6.2, 12.0)	4.20 (br d, <i>ca.</i> 12)
9	1.81 (3H, d, 1.0)	2.14 (3H, br s)
10	1.71 (3H, br s)	1.70 (3H, br s)
Glc-1'	4.34 (d, 7.8)	4.23 (d, 7.7)
2'	3.23 (dd, 7.8, 9.2)	3.19 (dd, 7.7, 9.1)
3'	3.45 (dd, 8.8, 9.2)	3.34 (dd, 8.9, 9.1)
4'	3.37 (dd, 8.8, 9.6)	3.28 (dd, 8.9, 9.5)
5'	3.31 (ddd, 2.6, 5.6, 9.6)	3.22 (ddd, 2.2, 5.9, 9.5)
6'	3.69 (dd, 5.6, 12.0)	3.66 (dd, 5.9, 11.8)
	3.86 (dd, 2.6, 12.0)	3.85 (dd, 2.2, 11.8)

Fig. 2. ¹H-¹H COSY and HMBC, Correlations for **4** and **5**

with those of **4a**, a glycosylation shift was observed at the 8-position (δ_C **4**: 65.5; **4a**: 59.4). The position of the glucoside linkage was also confirmed by HMBC experiments as shown in Fig. 2. Consequently, the stereostructure of **4** was clarified to be (2*E*,6*E*)-8- β -D-glucopyranosyloxy-2,6-dimethyl-2,6-octadienoic acid. On the other hand, the ¹H- and ¹³C-NMR data of **5** (CD₃OD, Tables 2, 3) indicated the presence of a (2*E*,6*E*)-8-hydroxy-3,7-dimethyl-2,6-octadienoic acid moiety [δ 1.70 (3H, br s, 10-H₃), 2.14 (3H, br s, 9-H₃), 2.24 (2H, m, 4-H₂), 2.27 (2H, m, 5-H₂), 4.05, 4.20 (1H each, both br d, $J=ca. 12$ Hz, 8-H₂), 5.47 (1H, tq, $J=7.1, 0.9$ Hz, 6-H), 5.67 (1H, br s, 1-H)] together with a β -D-glucopyranosyl part [δ 4.23 (d, $J=7.7$ Hz, 1'-H)]. The connectivity of the β -D-glucopyranosyl moiety in **5** was elucidated on the basis of HMBC experiments as shown in Fig. 2. Furthermore, a typical glycosylation shift was observed for the signals at 8-position (δ_C **5**: 75.6; **5a**: 68.8). On the basis of the above-mentioned evidence, the stereostructure of **5** was determined to be (2*E*,6*E*)-8- β -D-glucopyranosyloxy-3,7-dimethyl-2,6-octadienoic acid.

Effects of the Constituents on Tumor Necrosis Factor- α (TNF- α)-induced Cytotoxicity in L929 Cells TNF- α is known to mediate a variety of organ injury through its induction of cellular apoptosis. In the case of liver, the biological effects of TNF- α have been implicated in hepatic injury induced by hepatic toxins, ischemia/reperfusion, viral hepatitis, and alcohol.²²⁻²⁴ Therefore, TNF- α is considered to be an important target to discover anti-inflammatory and hepatoprotective agents. On the basis of above-mentioned concept, we investigated protective constituents from naturally occurring products on TNF- α -induced cell death in L929 cells, a TNF- α -sensitive cell line.²⁵ Previously, we have reported

Table 4. Inhibitory Effects of Constituents from Stems of *C. tubulosa* on TNF- α -Induced Cytotoxicity in L929 Cells

	Inhibition (%)				
	0 μ M	3 μ M	10 μ M	30 μ M	100 μ M
6-Deoxycatalpol (6)	0.0 $\pm$ 1.2	1.3 $\pm$ 2.1	1.1 $\pm$ 1.9	-1.9 $\pm$ 2.4	0.2 $\pm$ 3.5
Bartsioside (7)	0.0 $\pm$ 0.4	1.4 $\pm$ 2.0	5.5 $\pm$ 2.2	6.1 $\pm$ 2.0	1.1 $\pm$ 1.6
Kankanoside A (9)	0.0 $\pm$ 0.9	8.8 $\pm$ 2.7	15.5 $\pm$ 3.1**	17.2 $\pm$ 3.7**	16.3 $\pm$ 2.0**
Mussaenosidic acid (10)	0.0 $\pm$ 3.5	10.8 $\pm$ 6.9	26.5 $\pm$ 7.7*	72.0 $\pm$ 1.6**	44.7 $\pm$ 8.7**
8-Epiloganic acid (11)	0.0 $\pm$ 1.5	8.0 $\pm$ 2.8	4.3 $\pm$ 1.9	9.7 $\pm$ 2.2*	10.7 $\pm$ 0.4**
Geniposidic acid (13)	0.0 $\pm$ 2.5	2.3 $\pm$ 1.8	19.8 $\pm$ 3.9**	24.1 $\pm$ 1.5**	-2.5 $\pm$ 3.4
Kankanoside E (14)	0.0 $\pm$ 3.7	-5.4 $\pm$ 7.2	15.8 $\pm$ 2.9	19.3 $\pm$ 2.6	2.1 $\pm$ 12.1
(2E,6Z)-8- β -D-Glucopyranosyloxy-2,6-dimethyl-2,6-octadienoic acid (15)	0.0 $\pm$ 1.6	5.0 $\pm$ 3.0	3.3 $\pm$ 5.0	4.2 $\pm$ 2.7	2.8 $\pm$ 2.7
(2E,6E)-3,7-Dimethyl-8-hydroxyoctadien-1-yl-O- β -D-glucopyranoside (16)	0.0 $\pm$ 1.1	-2.5 $\pm$ 0.5	-1.5 $\pm$ 1.6	-2.8 $\pm$ 2.7	-8.1 $\pm$ 2.4
8-Hydroxygeraniol 8-O- β -D-glucopyranoside (17)	0.0 $\pm$ 3.1	3.6 $\pm$ 6.0	4.4 $\pm$ 7.9	9.9 $\pm$ 3.3	21.3 $\pm$ 2.4**
(+)-Pinoresinol O- β -D-glucopyranoside (22)	0.0 $\pm$ 1.3	4.1 $\pm$ 3.3	10.1 $\pm$ 5.8	13.9 $\pm$ 3.3*	22.3 $\pm$ 1.6**
(+)-Syringaresinol O- β -D-glucopyranoside (25)	0.0 $\pm$ 0.8	4.5 $\pm$ 4.5	-1.4 $\pm$ 2.9	-0.4 $\pm$ 2.0	-2.3 $\pm$ 4.3
Echinacoside ⁵⁾	0.0 $\pm$ 4.8	5.2 $\pm$ 3.5	22.5 $\pm$ 1.6**	45.7 $\pm$ 6.0**	80.4 $\pm$ 4.5**
Acteoside ⁵⁾	0.0 $\pm$ 1.1	16.4 $\pm$ 1.3*	24.1 $\pm$ 4.6**	58.4 $\pm$ 2.5**	91.9 $\pm$ 5.3**
Isoacteoside ⁵⁾	0.0 $\pm$ 1.2	-4.6 $\pm$ 3.5	19.0 $\pm$ 2.6**	61.9 $\pm$ 5.9**	102.4 $\pm$ 8.7**

Each value represents the mean $\pm$ S.E.M. ($n=4$). Significantly different from the control, * $p<0.05$, ** $p<0.01$.

that several constituents from *Piper chaba*,^{26–29)} *Boesenbergia rotunda*,^{30,31)} *Punica granatum*,³²⁾ *Helichrysum arenarium*,^{33–35)} and *Sapindus rarak*,^{36–38)} were found to show inhibitory effects of TNF- α -induced cytotoxicity in L929 cells. Since the phenylethanoid constituents of *C. tubulosa* (e.g. echinacoside, acteoside, and isoacteoside, etc.)⁵⁾ were also inhibited this cytotoxicity, we further examined iridoid, phenylpropanoid, and lignan constituents as shown in Table 4. As the result, kankanoside A (9, inhibition: 16.3 $\pm$ 2.0% at 100 μ M), mussaenosidic acid (10, 44.7 $\pm$ 8.7%), 8-epiloganic acid (11, 10.7 $\pm$ 0.4%), 8-hydroxygeraniol 8-O- β -D-glucopyranoside (17, 21.3 $\pm$ 2.4%), and (+)-pinoresinol O- β -D-glucopyranoside (22, 22.3 $\pm$ 1.6%), were found to show significant activity. Although their activities were weaker than those of echinacoside (IC₅₀=31.1 μ M), acteoside (17.8 μ M), and isoacteoside (22.7 μ M), the principle phenylethanoid constituents.⁵⁾

Experimental

The following instruments were used to obtain spectral and physical data: specific rotations, Horiba SEPA-300 digital polarimeter ($l=5$ cm); UV spectra, Shimadzu UV-1600 spectrometer; IR spectra, Shimadzu FTIR-8100 spectrometer; ¹H- and ¹³C-NMR spectra, JEOL JNM-ECA600 (600, 150 MHz) and JEOL JNM-ECS400 (400, 100 MHz) spectrometers with tetramethylsilane as an internal standard; FAB-MS and high-resolution FAB-MS, JEOL JMS-SX 102A mass spectrometer; HPLC detector, Shimadzu RID-10A refractive index, Shimadzu SPD-10A UV-VIS, and Shodex OR-2 optical rotation detectors. HPLC column, Cosmosil 5C₁₈-MS-II and π NAP (Nacalai Tesque Inc., 250 $\times$ 4.6 mm i.d.) and (250 $\times$ 20 mm i.d.) columns were used for analytical and preparative purposes, respectively.

The following experimental conditions were used for chromatography: normal-phase silica gel column chromatography (CC), silica gel 60N (Kanto Chemical Co., Ltd., 63–210 mesh, spherical, neutral); reversed-phase silica gel CC, Diaion HP-20 (Nippon Rensui) and Chromatorex ODS DM1020T (Fuji Silysia Chemical, Ltd., 100–200 mesh); normal-phase TLC, pre-coated TLC plates with silica gel 60F₂₅₄ (Merck, 0.25 mm); reversed-phase TLC, pre-coated TLC plates with silica gel RP-18 F_{254S} (Merck, 0.25 mm); reversed-phase HPTLC, pre-coated TLC plates with silica gel RP-18 WF_{254S} (Merck, 0.25 mm), detection was achieved by spraying with 1% Ce(SO₄)₂-10% aqueous H₂SO₄, followed by heating.

Plant Material This item was described in a previous report.⁵⁾

Extraction and Isolation Fresh stems of *C. tubulosa* (2.98 kg) were finely cut and extracted three times with methanol under reflux for 3 h. Evaporation of the solvent under reduced pressure provided a methanolic extract (249.1 g, 8.36%). The methanolic extract was subjected to Diaion HP-20 CC (5.0 kg, H₂O $\rightarrow$ MeOH) to give H₂O- and MeOH-eluted fractions

(167.84 g, 5.63% and 81.21 g, 2.73%, respectively). The MeOH-eluted fraction (61.00 g) was subjected to normal-phase silica gel CC [1.8 kg, CHCl₃-MeOH-H₂O (15:3:0.4 $\rightarrow$ 10:3:0.5 $\rightarrow$ 6:4:1, v/v/v) $\rightarrow$ MeOH] to give seven fractions [Fr. 1 (1.12 g), 2 (9.56 g), 3 (0.89 g), 4 (10.69 g), 5 (8.84 g), 6 (12.52 g), and 7 (4.60 g)], as was described previously.⁵⁾ The fraction 1 (1.12 g) was separated by reversed-phase silica gel CC [55 g, MeOH-H₂O (40:60, v/v) $\rightarrow$ MeOH] to give five fractions [Fr. 1-1 (132.8 mg), 1-2 (267.0 mg), 1-3 (182.8 mg), 1-4 (310.9 mg), and 1-5 (91.4 mg)]. The fraction 1-1 (132.8 mg) was further purified by HPLC [Cosmosil 5C₁₈-MS-II, CH₃CN-1% aqueous AcOH (10:90, v/v)] to give kankanoside M (2, 2.8 mg, 0.0001%), bartsioside (7, 5.2 mg, 0.0002%), sinapic aldehyde 4-O- β -D-glucopyranoside (21, 1.4 mg, 0.0001%). The fraction 1-2 (267.0 mg) was further purified by HPLC [Cosmosil 5C₁₈-MS-II, CH₃CN-1% aqueous AcOH (7:93, v/v)] to give (2E,6E)-3,7-dimethyl-8-hydroxyoctadien-1-yl-O- β -D-glucopyranoside (16, 15.8 mg, 0.0007%), 8-hydroxygeraniol 8-O- β -D-glucopyranoside (17, 5.2 mg, 0.0002%), (+)-pinoresinol O- β -D-glucopyranoside (22, 22.0 mg, 0.0010%), eucemmin A (23, 5.0 mg, 0.0002%), isoeucemmin A (24, 21.3 mg, 0.0010%), and (+)-syringaresinol O- β -D-glucopyranoside (25, 98.0 mg, 0.0044%). The fraction 2 (9.56 g) was separated by reversed-phase silica gel CC [400 g, MeOH-H₂O (10:90, v/v) $\rightarrow$ MeOH $\rightarrow$ acetone] to give five fractions [Fr. 2-1 (55.9 mg), 2-2 (4.48 g), 2-3 (3.42 g), 2-4 (1.16 g), and 2-5 (31.9 mg)], as was described previously.⁵⁾ The fraction 2-2 (500.0 mg) was subjected to HPLC [Cosmosil 5C₁₈-MS-II, CH₃CN-1% aqueous AcOH (5:95, v/v)] to give kankanoside L (1, 6.6 mg, 0.0026%) and 6-deoxycatalpol (6, 455.5 mg, 0.182%). The fraction 2-3 (1.00 g) was subjected to HPLC [Cosmosil 5C₁₈-MS-II, CH₃CN-1% aqueous AcOH (7:93, v/v)] to give seven fractions [Fr. 2-3-1 (66.5 mg), 2-3-2 (20.4 mg), 2-3-3 (26.0 mg), 2-3-4 (136.6 mg), 2-3-5 [=7 (380.6 mg, 0.0581%)], 2-3-6 [=glucoside (8, 285.1 mg, 0.0435%)], and 2-3-7 (84.9 mg)]. The fraction 2-3-4 (106.6 mg) was further purified by HPLC [Cosmosil π NAP, CH₃CN-1% aqueous AcOH (5:95, v/v)] to give 6 (68.4 mg, 0.0134%) together with salidoside⁵⁾ (13.7 mg, 0.0027%). The fraction 2-4 (1.16 g) was subjected to HPLC [Cosmosil 5C₁₈-MS-II, CH₃CN-1% aqueous AcOH (15:85, v/v) and Cosmosil π NAP, CH₃CN-1% aqueous AcOH (10:90 or 15:85, v/v)] to give kankanosides N (3, 15.6 mg, 0.0007%), O (4, 44.1 mg, 0.0020%), and P (5, 4.2 mg, 0.0002%), 6 (24.0 mg, 0.0011%), 8 (17.7 mg, 0.0008%), kankanoside A (9, 22.3 mg, 0.0010%), 8-epideoxyloganic acid (12, 8.1 mg, 0.0004%), kankanoside E (14, 58.1 mg, 0.0026%), (2E,6Z)-8- β -D-glucopyranosyloxy-2,6-dimethyl-2,6-octadienoic acid (15, 31.0 mg, 0.0014%), 16 (168.6 mg, 0.0075%), 17 (94.3 mg, 0.0042%), betulalbuside A (18, 8.1 mg, 0.0004%), coniferin (19, 3.8 mg, 0.0002%), and syringin (20, 33.9 mg, 0.0015%). The fraction 4 (10.69 g) was separated by reversed-phase silica gel CC [500 g, MeOH-H₂O (30:70, v/v) $\rightarrow$ MeOH $\rightarrow$ acetone] to give four fractions [Fr. 4-1 (878.2 mg), 4-2 (7.06 g), 4-3 (1.57 g), and 4-4 (792.8 mg)], as was described previously.⁵⁾ The fraction 4-1 (500.0 mg) was purified by HPLC [Cosmosil 5C₁₈-MS-II, CH₃CN-1% aqueous AcOH (10:90, v/v)] to give mussaenosidic acid (10, 39.1 mg, 0.0031%) and geniposidic acid (13, 51.2 mg, 0.0040%). The fraction 5 (8.84 g) was separated by reversed-phase silica gel CC [400 g, MeOH-H₂O (20:80 $\rightarrow$ 30:70, v/v) $\rightarrow$ MeOH $\rightarrow$ acetone] to give seven fractions [Fr. 5-1 (870.2 mg), 5-2 (478.9 mg), 5-3 (3.72 g), 5-4

(979.9 mg), 5-5 (1.19 g), 5-6 (1.27 g), and 5-7 (130.1 mg)], as was described previously.⁵⁾ The fraction 5-1 (870.2 mg) was further purified by HPLC [Cosmosil π NAP, CH₃CN–1% aqueous AcOH (5:95, v/v)] to give **10** (55.3 mg, 0.0025%) and 8-epilogonic acid (**11**, 51.5 mg, 0.0023%).

Kankanoside L (1): A white powder, $[\alpha]_D^{26} -45.7$ ($c=0.48$, MeOH). High-resolution positive-ion FAB-MS: Calcd for C₁₅H₂₄O₈Na [M+Na]⁺ 371.1318; Found 371.1309. IR (KBr, cm⁻¹): 3433, 2928, 1080. ¹H-NMR (600 MHz, CD₃OD) δ : given in Table 1. ¹³C-NMR (150 MHz, CD₃OD) δ : given in Table 2. Positive-ion FAB-MS m/z : 371 [M+Na]⁺. Negative-ion FAB-MS m/z : 347 [M-H]⁻.

Kankanoside M (2): A white powder, $[\alpha]_D^{26} -18.7$ ($c=0.11$, MeOH). High-resolution positive-ion FAB-MS: Calcd for C₁₅H₂₂O₈Na [M+Na]⁺ 353.1212; Found 353.1208. IR (KBr, cm⁻¹): 3433, 2924, 1736, 1655, 1076. ¹H-NMR (600 MHz, CD₃OD) δ : given in Table 1. ¹³C-NMR (150 MHz, CD₃OD) δ : given in Table 2. Positive-ion FAB-MS m/z : 353 [M+Na]⁺.

Kankanoside N (3): A white powder, $[\alpha]_D^{25} -24.6$ ($c=1.00$, MeOH). High-resolution positive-ion FAB-MS: Calcd for C₁₆H₂₈O₈Na [M+Na]⁺ 371.1682; Found 371.1686. IR (KBr, cm⁻¹): 3415, 2874, 1076, 1028. ¹H-NMR (600 MHz, CD₃OD) δ : given in Table 1. ¹³C-NMR (150 MHz, CD₃OD) δ : given in Table 2. Positive-ion FAB-MS m/z : 371 [M+Na]⁺.

Kankanoside O (4): A white powder, $[\alpha]_D^{23} -26.1$ ($c=2.30$, MeOH). High-resolution positive-ion FAB-MS: Calcd for C₁₆H₂₆O₈Na [M+Na]⁺ 369.1525; Found 369.1528. UV [$\lambda_{\max}$ (log ϵ), MeOH, nm]: 217 (4.04). IR (KBr, cm⁻¹): 3433, 2926, 1696, 1647, 1076. ¹H-NMR (600 MHz, CD₃OD) δ : given in Table 3. ¹³C-NMR (150 MHz, CD₃OD) δ : given in Table 2. Positive-ion FAB-MS m/z : 369 [M+Na]⁺.

Kankanoside P (5): A white powder, $[\alpha]_D^{21} -32.7$ ($c=0.18$, MeOH). High-resolution positive-ion FAB-MS: Calcd for C₁₆H₂₆O₈Na [M+Na]⁺ 369.1525; Found 369.1520. UV [$\lambda_{\max}$ (log ϵ), MeOH, nm]: 217 (4.08). IR (KBr, cm⁻¹): 3434, 2926, 1701, 1647, 1076. ¹H-NMR (600 MHz, CD₃OD) δ : given in Table 3. ¹³C-NMR (150 MHz, CD₃OD) δ : given in Table 2. Positive-ion FAB-MS m/z : 369 [M+Na]⁺.

Acid Hydrolysis of Kankanosides L–P (1–5) Solutions of **1–5** (each 1.0 mg) in 1.0 M HCl (1.0 ml) were heated at 80 °C for 3 h. After being cooled, the reaction mixture was neutralized with Amberlite IRA-400 (OH⁻ form), and the resins were removed by filtration. After removal of the solvent under reduced pressure, the residue was separated by Sep-Pak C₁₈ cartridge column (H₂O→MeOH). The H₂O-eluted fraction was subjected to HPLC analysis under following conditions: HPLC column, Kaseisorb LC NH₂-60-5, 4.6 mm i.d.×250 mm (Tokyo Kasei Co., Ltd., Tokyo, Japan); detection, optical rotation [Shodex OR-2 (Showa Denko Co., Ltd., Tokyo, Japan); mobile phase, CH₃CN–H₂O (85:15, v/v); flow rate 0.8 ml/min]. Identification of D-glucose present in the H₂O-eluted fractions of **1–5** were carried out by comparison of their retention times and optical rotation with that of an authentic sample [t_R 17.9 min (positive)].

Hydrogenation of 6-Deoxycatalpol (6) A suspension of **6** (12.0 mg) and 10% palladium carbon (5.0 mg) in MeOH (2.0 ml) was stirred at room temperature under an H₂ atmosphere for 2 h. The catalyst was filtered off, and the filtrate was condensed under reduced pressure to give **1** (12.0 mg, quant.).

Enzymatic Hydrolysis of Kankanosides O (4) and P (5) with β -Glucosidase To a solution of **4** (8.0 mg) in H₂O (1.5 ml) was added β -glucosidase (4.7 mg, from almond, Oriental Yeast Co., Tokyo, Japan), and the solution was stirred at 37 °C for 24 h. The reaction was quenched by the addition of EtOH (5.0 ml), the mixture was condensed under reduced pressure. The residue was extracted with EtOAc and evaporation of the solvent gave (2*E*,6*E*)-8-hydroxy-2,6-dimethyl-2,6-octadienoic acid²⁰⁾ (**4a**, 3.9 mg, 92%). Through a similar procedure, (2*E*,6*E*)-8-hydroxy-3,7-dimethyl-2,6-octadienoic acid²¹⁾ (**5a**, 0.9 mg, 94%) was obtained from kankanoside P (**5**, 1.8 mg).

Bioassay Method Inhibitory effect on TNF- α -induced cytotoxicity in L929 cells was assayed by the method described in a previous paper.⁵⁾

Statistics Values are expressed as means±S.E.M. One-way analysis of variance (ANOVA) followed by Dunnett's test was used for statistical analysis. Probability (p) values less than 0.05 were considered significant.

Acknowledgements This work was supported by 'High-Tech Research Center' Project for Private Universities: matching fund subsidy from MEXT (Ministry of Education, Culture, Sports, Science and Technology), 2007–2011 and a Grant-in Aid for Scientific Research from MEXT.

References and Notes

- Kobayashi H., Oguchi H., Takizawa N., Miyase T., Ueno A., Usmanghani K., Ahmad M., *Chem. Pharm. Bull.*, **35**, 3309–3314 (1987).
- Xinjiang Science and Technology Press, "Culture Techniques of Xinjiang Staple Medicinal Plants," ed. by Xinjiang Institute of Traditional Chinese and Ethnologic Medicines, 2004, pp. 84–88.
- Xie H., Morikawa T., Matsuda H., Nakamura S., Muraoka O., Yoshikawa M., *Chem. Pharm. Bull.*, **54**, 669–675 (2006).
- Yoshikawa M., Matsuda H., Morikawa T., Xie H., Nakamura S., Muraoka O., *Bioorg. Med. Chem.*, **14**, 7468–7475 (2006).
- Morikawa T., Pan Y., Ninomiya K., Imura K., Matsuda H., Yoshikawa M., Yuan D., Muraoka O., *Bioorg. Med. Chem.*, **18**, 1882–1890 (2010).
- Pan Y., Morikawa T., Ninomiya K., Imura K., Yuan D., Yoshikawa M., Muraoka O., *Chem. Pharm. Bull.*, **58**, 575–578 (2010).
- Kobayashi H., Karasawa H., Miyase T., Fukushima S., *Chem. Pharm. Bull.*, **33**, 3645–3650 (1985).
- Yoshizawa F., Deyama T., Takizawa N., Usmanghani K., Ahmad M., *Chem. Pharm. Bull.*, **38**, 1927–1930 (1990).
- Wang S. J., Pei Y. H., Hua H. M., *Chin. Chem. Lett.*, **12**, 343–344 (2001).
- Sekiya Y., Mizuno Y., Yamamoto Y., Kubota K., Kobayashi A., Koshino H., *Biosci. Biotechnol. Biochem.*, **63**, 384–389 (1999).
- Kasai R., Fujino H., Kuzuki T., Wong W.-H., Goto C., Yata N., Tanaka O., Yasuhara F., Yamaguchi S., *Phytochemistry*, **25**, 871–876 (1986).
- Morikawa H., Kasai R., Otsuka H., Hirata E., Shinzato T., Aramoto M., Takeda Y., *Chem. Pharm. Bull.*, **52**, 1086–1090 (2004).
- Sugiyama M., Nagayama E., Kikuchi M., *Phytochemistry*, **33**, 1215–1219 (1993).
- Ida Y., Satoh Y., Ohtsuka M., Nagasao M., Shoji J., *Phytochemistry*, **35**, 209–215 (1994).
- Chiba M., Hisada S., Nishibe S., Thieme H., *Phytochemistry*, **19**, 335–336 (1980).
- Deyama T., Ikawa T., Nishibe S., *Chem. Pharm. Bull.*, **33**, 3651–3657 (1985).
- Sugiyama M., Kikuchi M., *Chem. Pharm. Bull.*, **39**, 483–485 (1991).
- Kobayashi H., Karasawa H., Miyase T., Fukushima S., *Chem. Pharm. Bull.*, **33**, 1452–1457 (1985).
- The ¹H- and ¹³C-NMR spectra of **1–5** were assigned with the aid of distortionless enhancement by polarization transfer (DEPT), double quantum filter correlation spectroscopy (DQF COSY), heteronuclear multiple quantum coherence (HMQC), and heteronuclear multiple bond connectivity (HMBC) experiments.
- Iwagawa T., Asai H., Hase T., Sako S., Su R., Hagiwara N., Kim M., *Phytochemistry*, **29**, 1913–1916 (1990).
- Gering B., Wichtl M., *J. Nat. Prod.*, **50**, 1048–1054 (1987).
- Wang Y., Singh R., Lefkowitz J. H., Rigoli R. M., Czaja M. J., *J. Biol. Chem.*, **281**, 15258–15267 (2006).
- Tilg H., Day C. P., *Nat. Clin. Pract. Gastroenterol. Hepatol.*, **4**, 24–34 (2007).
- Seronello S., Sheikh M. Y., Choi J., *Free Radic. Biol. Med.*, **43**, 869–882 (2007).
- Kouroku Y., Fujita E., Jimbo A., Mukasa T., Tsuru T., Momoi M. Y., Momoi T., *Biochem. Biophys. Res. Commun.*, **270**, 972–977 (2000).
- Matsuda H., Ninomiya K., Morikawa T., Yasuda D., Yamaguchi I., Yoshikawa M., *Bioorg. Med. Chem. Lett.*, **18**, 2038–2042 (2008).
- Matsuda H., Ninomiya K., Morikawa T., Yasuda D., Yamaguchi I., Yoshikawa M., *Bioorg. Med. Chem.*, **17**, 7313–7323 (2009).
- Morikawa T., Yamaguchi I., Matsuda H., Yoshikawa M., *Chem. Pharm. Bull.*, **57**, 1292–1295 (2009).
- Morikawa T., *Yakugaku Zasshi*, **131**, 758–791 (2010).
- Yoshikawa M., Morikawa T., Funakoshi K., Ochi M., Pongpiriyadacha Y., Matsuda H., *Heterocycles*, **75**, 1639–1650 (2008).
- Morikawa T., Funakoshi K., Ninomiya K., Yasuda D., Miyagawa K., Matsuda H., Yoshikawa M., *Chem. Pharm. Bull.*, **56**, 956–962 (2008).
- Xie Y., Morikawa T., Ninomiya K., Imura K., Muraoka O., Yuan D., Yoshikawa M., *Chem. Pharm. Bull.*, **56**, 1628–1631 (2008).
- Morikawa T., Wang L.-B., Nakamura S., Ninomiya K., Yokoyama E., Matsuda H., Muraoka O., Wu L.-J., Yoshikawa M., *Chem. Pharm. Bull.*, **57**, 361–367 (2009).
- Wang L.-B., Morikawa T., Nakamura S., Ninomiya K., Matsuda H., Muraoka O., Wu L.-J., Yoshikawa M., *Heterocycles*, **78**, 1235–1242 (2009).
- Morikawa T., Wang L.-B., Ninomiya K., Nakamura S., Matsuda H., Muraoka O., Wu L.-J., Yoshikawa M., *Chem. Pharm. Bull.*, **57**, 853–859 (2009).
- Morikawa T., Xie Y., Asao Y., Okamoto M., Yamashita C., Muraoka O., Matsuda H., Pongpiriyadacha Y., Yuan D., Yoshikawa M., *Phytochemistry*, **70**, 1166–1172 (2009).
- Asao Y., Morikawa T., Xie Y., Okamoto M., Hamao M., Matsuda H., Muraoka O., Yuan D., Yoshikawa M., *Chem. Pharm. Bull.*, **57**, 198–203 (2009).
- Morikawa T., Xie Y., Ninomiya K., Okamoto M., Muraoka O., Yuan D., Yoshikawa M., Hayakawa T., *Chem. Pharm. Bull.*, **58**, 1276–1280 (2010).